The company said on January January 22, 2024 that it increased the size of its board from eleven to twelve and filled the open seat by appointing Reshema Kemps-Polanco as a director.

1. 01

   The company said on January January 22, 2024 that it increased the size of its board from eleven to twelve and filled the open seat by appointing Reshema Kemps-Polanco as a director.

2. 02

   The company said it assigned director Kemps-Polanco to the existing Compensation Committee and Strategic Planning and Capital Allocation Committee, and that there are no arrangements with any other person related to her selection and no transactions requiring disclosure under Item 404(a).

3. 03

   The company said Kemps-Polanco will take part in the non-employee director compensation program, with an annual equity award value before pro-rata adjustment of $255,500, issued as 50% restricted stock units and 50% stock options.

4. 04

   The company said Kemps-Polanco has 25 years of pharmaceutical industry experience and currently serves as Executive Vice President and Chief Commercial Officer of Novartis US, and that she held leadership positions at Johnson & Johnson from 2014 to 2021.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.